Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS FXI-LRx in Healthy Volunteers
NCT03582462Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Apr 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fesomersen in thrombosis (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events up to 232 Days. Started Jul 2018; status: completed.
02
Drugs
fesomersen
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03582462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03582462.